WO2017118885A1 - Compositions pharmaceutiques stables de calcitriol - Google Patents

Compositions pharmaceutiques stables de calcitriol Download PDF

Info

Publication number
WO2017118885A1
WO2017118885A1 PCT/IB2016/057425 IB2016057425W WO2017118885A1 WO 2017118885 A1 WO2017118885 A1 WO 2017118885A1 IB 2016057425 W IB2016057425 W IB 2016057425W WO 2017118885 A1 WO2017118885 A1 WO 2017118885A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcitriol
mixtures
sodium
pharmaceutical
composition
Prior art date
Application number
PCT/IB2016/057425
Other languages
English (en)
Inventor
Sagar PRASANNA
Trivedi ASHISH MAHESHKUMAR
Jain SACHIN
Utage MAHESH SHIVRUDRAPPA
Bala Satish R
Venkat Ramireddy K.
Patel SAPNIL KUMAR
Mohan PADALA
Original Assignee
Gland Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gland Pharma Limited filed Critical Gland Pharma Limited
Publication of WO2017118885A1 publication Critical patent/WO2017118885A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3

Definitions

  • the present invention relates to stable clear colorless liquid pharmaceutical compositions of calcitriol with butylated hydroxy toluene and/ or butylated hydroxy anisole.
  • Calcitriol also known as 9, 10-Secocholesta-5,7, 10( 19)-triene- l ,3,25-triol, 1 a, 25- dihydroxycholecalciferol, or la, 25-dihydroxyvitamin D3, is the biologically active form of vitamin D3 which promotes intestinal calcium transport and bone calcium resorption. Calcitriol was first identified by Michael F. Holick in work published in 1971 . The preparation, isolation, identification and biological activity of 1 ,25-dihydroxycholecalciferol (Calcitriol) are disclosed in U.S. patent No. 3,697,559.
  • Calcitriol increases blood calcium levels ([Ca 2+ ]) by promoting absorption of dietary calcium from the gastrointestinal tract and increasing renal tubular reabsorption of calcium, thus reducing the loss of calcium in the urine.
  • Calcitriol is approved in US as injection, oral capsule, oral solution and topical ointment.
  • Calcitriol is supplied commercially as Rocaltrol® (calcitriol) capsules (Roche Labs) provide a solid tablets and solution for oral administration, while Calcijex® (calcitriol) (Abbvie) provides a solution for intravenous administration, which is particularly useful for chronic renal dialysis patients and topical ointment by Galderma Labs.
  • Calcitriol is commercially available as ampoules and vials. The headspace of the calcitriol ampoule is filled with nitrogen gas to provide an inert atmosphere.
  • the solution retains some oxygen and the reaction of the metal ascorbate antioxidant with the residual oxygen ultimately causes the clear solution to turn yellow. Since drug products are periodically inspected for discoloration, a significant amount of therapeutically useful product is discarded due to antioxidant discoloration.
  • Disadvantages of ampoules are sealed glass ampoules must be broken open in order to access the medication, exposing the health care provider to risk of injury from broken glass. Glass fragments can enter the solution as the ampoule is broken, often requiring the use of a sterile filter, with additional effort and expense, to remove the solution from the open ampoule. Breaking the ampoule is usually done in a non- sterile environment, increasing the risk of both microbial and blood contamination. The ampoule has broken glass edges which are difficult to sterilize before the needle is inserted. Once the ampoule is broken the entire contents must be used or, if only a part of the contents are used, the remainder must be discarded.
  • U.S. patent No. 6,051 ,567 and its family equivalent patents U.S. patent No. 6,265,392 and U.S. patent No. 6,247, 169 claims a stable aqueous formulations comprising Calcitriol, polysorbate 20, sodium ascorbate, hydrochloric acid or sodium hydroxide to adjust the pH, water for injection and in a sealed vessel, having no more than about 2.0% of oxygen in the headspace of the container. Though sodium ascorbate is used as an antioxidant in the composition and head space maintained with less than 2.0% oxygen, the composition gets degraded and does not provide the required potency to the product.
  • U.S. patent No. 6,21 1 , 169 patent disclose liquid Calcitriol formulations for intravenous administration.
  • the invention relates to a calcitriol solution, and a method for preparing the solution, which is suitable for packaging into vials.
  • This composition though present in vials uses sodium ascorbate as antioxidant in the finished product composition.
  • WO 2016103722 patent application disclose vitamin D 3 derivatives for treating different diseases.
  • U.S. patent application No. 20150045333 disclose stable liquid emulsion composition comprising vitamin D or a salt thereof, with sorbate and benzoate.
  • Calcitriol injection is mentioned as colorless to yellow aqueous solution. Though they are colorless solution but would turn to yellow solution after coming in contact with environment. The color change is also affecting the appearance with reduced EDTA content and with reduced potency.
  • inventive subject matter is drawn to stable pharmaceutical liquid compositions and methods for Calcitriol in which calcitriol has significantly increased stability over prolonged periods of time.
  • Another object of the present invention is to prepare stable clear, colorless pharmaceutical liquid compositions of Calcitriol which remains clear, colorless during the shelf life of the product.
  • aspects of the present invention relate to a stable clear, colorless pharmaceutical liquid composition comprising Calcitriol or its pharmaceutically acceptable salt thereof, with antioxidant other than metal ascorbate and other suitable excipients.
  • Another aspect relates to a stable clear, colorless pharmaceutical liquid composition
  • Calcitriol or its pharmaceutically acceptable salt thereof with antioxidant other than metal ascorbate is butylated hydroxy toluene and butylated hydroxy anisole; and other suitable excipients.
  • the pharmaceutical liquid composition of above aspect is clear, colorless during shelf life and is suitable for autoclaving at 121°C for 15 minutes.
  • suitable excipients include, solubilizer or surfactant comprising selected from polyoxyethylene sorbitan monooleate (polysorbate 80), sorbitan monooleate, polyoxyethylene sorbitan monolaurate (polysorbate 20), lecithin, polyoxyethylene- polyoxypropylene copolymers (pluronics) or any mixtures thereof; antioxidant is selected from ascorbic acid, tocopherol, acetylcysteine, monothioglycerol, butylhydroxy toluene, butylhydroxy anisole, cystein, methionine, propyl gallate, thioglycolate sodium, and mixtures thereof; buffering agent selected from sodium phosphate monobasic or dibasic or any mixtures thereof; complexing agent such as sodium edetate (EDTA); tonicity contributing agent selected from sodium chloride, dextrose, sucrose, fructose, and mixtures thereof.
  • solubilizer or surfactant comprising selected from polyoxyethylene
  • composition of above aspect comprising:
  • the pharmaceutical composition of above aspects has about 95% potency of Calcitriol and about 100% potency of EDTA after autoclaving at 121 °C for 15 minutes.
  • the pharmaceutical composition of above aspects is clear and colorless and has about 93% potency of Calcitriol and about 100% potency of EDTA after autoclaving at 121 °C for 15 minutes for 1 month storage.
  • the pharmaceutical liquid composition according to above aspect, wherein said composition comprises from about 0.01 mcg/ml to about 10 mcg/ml of Calcitriol.
  • composition according to above aspect, wherein said composition comprises from about 0.05mcg/ml to about 5 mcg/ml of Calcitriol.
  • the present invention relates to stable clear colorless liquid pharmaceutical compositions of calcitriol and process of preparing the same.
  • active ingredient or drug refers to a substance that has a physiological effect when ingested or otherwise introduced into the body, in particular or a chemical substance used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being.
  • pharmaceutically acceptable refers to substances that are useful in preparing a pharmaceutical composition that are generally non-toxic and not biologically undesirable, and includes materials acceptable for veterinary use and/or human pharmaceutical use.
  • compositions suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • excipient or "pharmaceutically acceptable excipient” means a component of a pharmaceutical product that is not a pharmacologically active ingredient, such as filler, diluent, carrier, preservative, etc.
  • excipients that are useful in preparing pharmaceutical compositions are generally safe, non-toxic, and neither biologically nor otherwise undesirable, and are acceptable for veterinary use as well as human pharmaceutical use.
  • the term includes both one and more than one such excipients.
  • composition is intended to encompass a combination including active ingredients and pharmaceutically acceptable excipients, as well as any product which results, directly or indirectly, from combination, complexation, or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions involving one or more of the ingredients.
  • formulation or “dosage form” or “composition” refers to finished pharmaceutical products that are suitable for administration, including, but not limited to, injections, etc.
  • stable or “stability” as used herein includes both physical and chemical stability.
  • physical stability refers to maintenance of the form of active agents, such as crystalline or amorphous, and the term “chemical stability” relates to a limited formation of impurities.
  • Carrier or “vehicle” as used herein refers to pharmacologically inert materials that provide a more or less fluid matrix, suitable for topical drug administration. Carriers and vehicles useful herein include any such materials known in the art, which are nontoxic and do not interact with other components of a pharmaceutical formulation or drug delivery system in a deleterious manner. The topical formulations of the present invention are particularly suitable for parenteral administration.
  • Formulations suitable for parenteral dosage forms such as injectables such as intravenous, intramuscular or subcutaneous, implants and the like.
  • Other parenteral ingredients used in the formulation are generally those commonly used and recognized by persons skilled in the art of parenteral formulations.
  • the term "therapeutically effective amount" of a compound of this invention means an amount effective to modulate the formation or progression of a malaria infection in a host.
  • Calcitriol includes the compound Calcitriol, pharmaceutically acceptable salts and esters thereof, and any polymorphs, solvates and hydrates thereof.
  • antioxidant or “antioxidants” includes individual antioxidant or a combination or mixtures of antioxidant.
  • aspects of the present invention relate to innovative stable liquid pharmaceutical compositions of Calcitriol with antioxidants selected from butylated hydroxy toluene (BHT) and/or butylated hydroxy anisole (BHA) and suitable excipients.
  • antioxidants selected from butylated hydroxy toluene (BHT) and/or butylated hydroxy anisole (BHA) and suitable excipients.
  • Another aspect relates to liquid compositions which are suitable for autoclaving at 121 °C for 15 minutes.
  • the compositions were found to be stable subsequent to autoclaving and provided the required potency.
  • a storage stable liquid pharmaceutical composition that includes Calcitriol in a therapeutically effective amount.
  • the term "storage stable clear colorless liquid pharmaceutical composition” refers to a liquid pharmaceutical composition in which Calcitriol is dissolved in a solvent or solvent system, and in which at least 90% of the pharmaceutically active ingredient remain in an undegraded state after storage of the composition over one month after autoclaving at 121 °C for 15 minutes.
  • Another aspect relates to a composition which is suitable for autoclaving, wherein the commercially available compositions are unable to withstand heat and undergoes degradation to lose its potency.
  • the present invention has overcome those concerns and the advantage of the present invention is use of antioxidants BHA and /or BHT, which stabilizes the active ingredient Calcitriol and provides potency of about 95%. Further the disodium EDTA content is also highly stable.
  • the composition comprises a stable liquid composition comprising a substantially aqueous solvent system suitable for injection, an antioxidant, wherein the Calcitriol is present in the composition at a therapeutically effective concentration.
  • Calcitriol will be present at a concentration of about 0.01 mcg/ml to about 10 mcg/ml between 0.1 mg/ml to 10.0 mg/ml, and typically between about 0.05mcg/ml to about 5 mcg/ml, inclusive.
  • the present inventive composition is a clear colorless stable liquid composition even after storage for longer duration without any change in color, potency and EDTA content of the composition.
  • the pharmaceutical composition is clear colorless stable liquid composition and has about 93% potency of Calcitriol and about 100% potency of EDTA after autoclaving at 121 °C for 15 minutes after 1 month.
  • the antioxidant in such compositions has as a single and predominant component butylated hydroxy anisole and/or butylated hydroxy toluene.
  • the antioxidant in compositions essentially consists of butylated hydroxy anisole and/or butylated hydroxy toluene.
  • the composition may also include one or more additional antioxidants that are compatible and provide good stability with Calcitriol, and especially suitable antioxidants include propyl gallate, ascorbic acid, acetylcysteine, monothioglycerol and the like or any mixtures thereof.
  • suitable antioxidants include propyl gallate, ascorbic acid, acetylcysteine, monothioglycerol and the like or any mixtures thereof.
  • a liquid composition further comprises of excipients.
  • excipients such as solubilizer or surfactant comprising selected from Polyoxyethylene sorbitan monooleate (polysorbate 80), Sorbitan monooleate Polyoxyethylene sorbitan monolaurate (polysorbate 20), Polyoxyethylene sorbitan monopalmitate, Polyoxyethylene sorbitan trioleate, Lecithin, Polyoxyethylene- polyoxypropylene copolymers (Pluronics) or any mixtures thereof.
  • solubilizer or surfactants include, but not limited to Polyoxyethylene sorbitan monooleate (polysorbate 80), Sorbitan monooleate Polyoxyethylene sorbitan monolaurate (polysorbate 20) and the like or any mixtures thereof.
  • Another aspect relates to antioxidant selected from ascorbic acid, tocopherol, acetylcysteine, monothioglycerol, butylated hydroxy toluene, butylated hydroxy anisole, cystein, methionine, propyl gallate, thioglycolate sodium, and mixtures thereof.
  • antioxidants include but not limited to acetylcysteine, monothioglycerol, butylated hydroxy toluene, butylated hydroxy anisole, cystein and the like or any mixtures thereof.
  • buffers include citric acid buffer, acetic acid buffer, maleic acid buffer, phosphoric acid buffer, succinic acid buffer, and tartaric acid buffer and the ester forms of same.
  • buffers include but not limited to acid salt of the above buffers viz., sodium citrate, sodium phosphate, sodium acetate, sodium tartrate or any mixtures thereof.
  • complexing agent is selected from sodium ethylene diamine tetra acetic acid (EDTA), disodium EDTA, calcium disodium EDTA, Diethylenetriaminepenta acetic acid (DTPA) and the like or any mixtures thereof.
  • EDTA sodium ethylene diamine tetra acetic acid
  • DTPA Diethylenetriaminepenta acetic acid
  • complexing agents include but not limited to sodium ethylene diamine tetra acetic acid (EDTA), disodium EDTA, calcium disodium EDTA and the like or any mixtures thereof.
  • tonicity contributing agent include but not limited to sodium chloride, dextrose, sucrose, fructose, mannitol, calcium chloride, potassium chloride, sodium lactate and mixtures thereof.
  • tonicity contributing agent include but not limited to sodium chloride, dextrose, sucrose, or any mixtures thereof.
  • concentration of tonicity contributing agents used is as available in the general art to provide required osmolality.
  • Another aspect relates to process of preparing the Calcitriol composition:
  • step 2 calcitriol was added and dissolved in step 2 mixture and added to step 1 container mixture having water for injection.
  • EDTA sodium chloride, dibasic sodium phosphate, anhydrous and monobasic sodium phosphate were added and dissolved individually under nitrogen cover.
  • compositions of the present invention can be used to treat patient suffering from a disease sensitive to the treatment with Calcitriol, in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure, significantly reduce elevated parathyroid hormone levels.
  • Reduction of PTH has been shown to result in an improvement in renal osteodystrophy via various routes of administration such as intravenous, intramuscular, or subcutaneous injection.
  • a stability assessment was evaluated up to 6 months after storage at 25 ⁇ 5°C and 40 ⁇ 5°C till 3 months and the following tests were executed: pH appearance (colour, clarity/opalescence, particles; by visual inspection), pH, assay (by HPLC) and purity (by HPLC).
  • step 3 calcitriol was added and dissolved in step 2 mixture and added to step 1 container mixture having water for injection.
  • Example 4 Stability data of composition of calcitriol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition liquide incolore transparente stable comprenant du Calcitriol avec du butyl hydroxytoluène et/ou d'hydroxyanisole butylé; de plus, cette invention concerne une composition liquide innovante de Calcitriol.
PCT/IB2016/057425 2016-01-04 2016-12-08 Compositions pharmaceutiques stables de calcitriol WO2017118885A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641000206 2016-01-04
IN201641000206 2016-01-04

Publications (1)

Publication Number Publication Date
WO2017118885A1 true WO2017118885A1 (fr) 2017-07-13

Family

ID=59273413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/057425 WO2017118885A1 (fr) 2016-01-04 2016-12-08 Compositions pharmaceutiques stables de calcitriol

Country Status (1)

Country Link
WO (1) WO2017118885A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114831933A (zh) * 2022-05-07 2022-08-02 正大制药（青岛）有限公司 一种含有骨化三醇的口服溶液及其制备方法
CN116077432A (zh) * 2023-02-21 2023-05-09 正大制药（青岛）有限公司 一种骨化三醇口服溶液及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047595A1 (fr) * 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
WO2008027532A2 (fr) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions actives pharmacologiquement stables à base de vitamine d et de corticostéroïdes, compatibles avec un faible ph

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292080A1 (en) * 1998-09-11 2006-12-28 Connetics Australia Pty Ltd Vitamin formulation
WO2003047595A1 (fr) * 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
WO2008027532A2 (fr) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Compositions actives pharmacologiquement stables à base de vitamine d et de corticostéroïdes, compatibles avec un faible ph

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114831933A (zh) * 2022-05-07 2022-08-02 正大制药（青岛）有限公司 一种含有骨化三醇的口服溶液及其制备方法
CN116077432A (zh) * 2023-02-21 2023-05-09 正大制药（青岛）有限公司 一种骨化三醇口服溶液及其制备方法
CN116077432B (zh) * 2023-02-21 2023-09-08 正大制药（青岛）有限公司 一种骨化三醇口服溶液及其制备方法

Similar Documents

Publication Publication Date Title
US11446246B2 (en) Suspensions and diluents for metronidazole and baclofen
US20200188478A1 (en) Pre-mixed, ready to use vancomycin compositions
CN107810000B (zh) 来氟米林的可注射药物组合物
US20210378988A1 (en) Phytonadione compositions and related methods
AU2002309475B2 (en) Esmolol formulation
US20210361593A1 (en) Phytonadione compositions and related methods
WO2017118885A1 (fr) Compositions pharmaceutiques stables de calcitriol
EA036258B1 (ru) Стабильный препарат для парентерального введения тапентадола
WO2023072714A1 (fr) Phytonadione pour administration parentérale
JP2012517994A (ja) 高投与量ドラメクチン製剤
WO2022034614A1 (fr) Compositions de phytonadione
JP3668225B2 (ja) Ｏｃｔ製剤
EP1143962B1 (fr) Solution parenterale de propofol (2,6-diisoprophylphenol) et de 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol comme solvant
CA2974953A1 (fr) Formulations de 5-methyltrahydrofolate stables a utiliser pour moderer des polymorphismes associes a la methylenetetrahydrofolate reductase
JP2000219628A (ja) アラトロフロキサシンの予め混合した注射用組成物
WO2005004878A2 (fr) Recipients a multi-usage pour formulations de vitamine d
US10898452B2 (en) Stable formulation for parenteral administration of Tapentadol
EP2934524B1 (fr) Formulations vétérinaires injectables de pénéthamate
US20230181526A1 (en) Methods of efficiently treating vitamin c deficiency-related diseases and other conditions
US20230181525A1 (en) Ready-to-use ascorbic acid compound compositions
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16883497

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16883497

Country of ref document: EP

Kind code of ref document: A1